FORT WORTH, Texas, Sept. 26, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing...
FLORHAM PARK, N.J., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (Celularity), a clinical-stage biotechnology company developing placental-derived...
FLORHAM PARK, N.J., Sept. 23, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a...
Accomplished Operations Professional Promoted from Role as Director of Project Engineering; Credited with Leading All of the Company’s Ongoing Facility...
– Impacting more than 12 million people globally, HDV is the most aggressive form of viral hepatitis – – Novel...
FLORHAM PARK, N.J., Sept. 22, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a...
Two Abstracts Selected for Presentation as part of the Meeting’s Special Poster Collections Research Focuses on the Use of Thin...
• Upon closing of their proposed Business Combination, Ocean Biomedical will be a wholly owned subsidiary of Aesther Healthcare Acquisition...
Approximately 40% of Long COVID Patients Experience Multi-Site Pain Similar to Overlapping Chronic Pain Syndromes Fibromyalgia and ME/CFS Approximately 50%...
MIAMI, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for...
CINCINNATI, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), a...
Ongoing program to focus on checkpoint inhibitor refractory patients following data presented at ASCO 2022 demonstrating 77% survival at a...
A dozen global pharmaceutical companies have joined effort to accelerate critical therapies to citizens of the worldBURLINGAME, Calif., Sept. 20,...
Funds will advance research into ELI-007 as a mutant BRAF-peptide vaccine and ELI-008 as a p53 hotspot mutation-peptide vaccine, with...
COPENHAGEN, Denmark, September 20, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today that the board of directors has appointed...
Standard marketing authorization recommendation applies to all indications and formulations in the European Union, including COMIRNATY® Original/Omicron BA.4-5 and COMIRNATY®...
Sorrento has now completed its first Phase 1b human proof of concept study where the first 7 out of 7...
110 Patients Enrolled in Study Comparing Novel Gene-Mediated Immunotherapy plus Neoadjuvant Chemotherapy versus Neoadjuvant Chemotherapy Alone LAWRENCEVILLE, N.J., Sept. 15,...
SOUTH SAN FRANCISCO, Calif., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biopharmaceutical company focused...
Newly formed company founded by prominent Yale professors will advance development of novel RNA therapies and vaccine adjuvants for local...